Drug · CHEMBL704

MESALAMINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. MESALAMINE. Drugs and targets, record CHEMBL704. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL704

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: MESALAMINE; ChEMBL
ChEMBL ID: CHEMBL704; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Apriso, Asacol, Asacol hd, Canasa, Coltec ec, Delzicol, Ipocol, Lialda, Mesren mr, Mezavant xl, Octasa, Pentasa, Pentasa sr, Rowasa, Salofalk, Sfrowasa; ChEMBL
Other names: Benzoic acid, 5-amino-2-hydroxy-, Fisalamine, Iialda, MAX-002, Mesalazina, Mesalazine, NSC-38877; ChEMBL
DrugBank: DB00244; DrugBank
InChIKey: KBOPZPXVLCULAV-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 2 of its 22 diseases, from DailyMed, PMDA and TTD; Open Targets

Targets4

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
ALOX5	Polyunsaturated fatty acid 5-lipoxygenase	Arachidonate 5-lipoxygenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/240
PPARG	Peroxisome proliferator-activated receptor gamma	Peroxisome proliferator-activated receptor gamma agonist	AGONIST	https://conductscience.org/library/genes/5468
PTGS1	Cyclooxygenase	Cyclooxygenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/5742
PTGS2	Cyclooxygenase	Cyclooxygenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/5743

Source ChEMBL

Diseases22

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
ulcerative colitis	Approval	DailyMed, PMDA and TTD	125	78	https://conductscience.org/library/drugs?q=MONDO_0005101
Crohn disease	Phase 3	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=MONDO_0005011
irritable bowel syndrome	Phase 3	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=MONDO_0005052
HIV infectious disease	Phase 1/2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005109
diarrheal disease	Phase 2/3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0001673
inflammatory bowel disease	Unknown	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005265
Anal fissure	Phase 1/2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0012390
Blastocystis infectious disease	Phase 1/2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005671
Oral ulcer	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0000155
Pain	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0012531

1 to 10 of 22Source Open Targets

See all 22 diseases

Trials142

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 6 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00505778	A Comparison of Once a Day Dose Compared to 2 Doses/Day	Phase 3	1,027	2011-05-12	mesalamine	Its name	ClinicalTrials.gov
NCT00151892	Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis	Phase 3	829	2010-09-21	mesalazine	Its name	ClinicalTrials.gov
NCT01903252	TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)	Phase 3	817	2018-08-08	TP05, mesalazine	Its name	ClinicalTrials.gov
NCT01124149	Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis	Phase 4	759	2013-12-02	mesalamine	Its name	ClinicalTrials.gov
NCT00545103	Prevention of Recurrence of Diverticulitis	Phase 3	592	2012-12-19	mesalazine	Its name	ClinicalTrials.gov
NCT00545740	Prevention of Recurrence of Diverticulitis	Phase 3	590	2013-01-25	mesalamine	Its name	ClinicalTrials.gov
NCT00679432	(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis	Phase 3	510	2014-08-01	mesalamine	Its name	ClinicalTrials.gov
NCT01536535	Predicting Response to Standardized Pediatric Colitis Therapy	Phase 4	431	2019-08-28	mesalamine	Its name	ClinicalTrials.gov
NCT00326209	Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission	Phase 3	393	2019-11-01	mesalamine	Its name	ClinicalTrials.gov
NCT00073021	Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis	Phase 3	386	2011-07-28	mesalamine	Its name	ClinicalTrials.gov

1 to 10 of 142

See all 142 trials

Comparisons in its trials57

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
MMX Mesalamine/ Mesalazine (Acute Phase) vs MMX Mesalamine/ Mesalazine (Maintenance Phase): serious adverse events	13 of 717	14 of 461	1,178	NCT01124149	Trial comparisons
Mesalamine Once-Daily vs Mesalamine Twice-Daily: Number of Subjects Who Relapse/Flare Within 6 Months, ITT Population	45 of 512	39 of 511	1,023	NCT00505778	Trial comparisons
Mesalamine Once-Daily vs Mesalamine Twice-Daily: serious adverse events	18 of 512	9 of 511	1,023	NCT00505778	Trial comparisons
SPD476 vs Asacol: serious adverse events	6 of 415	3 of 411	826	NCT00151892	Trial comparisons
TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Rectal Bleeding Sub-score of 0	212 of 388	226 of 386	774	NCT01903252	Trial comparisons
TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Clinical Remission at Both Week 8 and 12	66 of 388	80 of 386	774	NCT01903252	Trial comparisons
TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Clinical Remission	92 of 388	110 of 386	774	NCT01903252	Trial comparisons
TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Clinical and Endoscopic Remission	87 of 388	95 of 386	774	NCT01903252	Trial comparisons
TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Clinical Response	223 of 388	233 of 386	774	NCT01903252	Trial comparisons
TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Clinical Response at Both Week 8 and Week 12	216 of 388	230 of 386	774	NCT01903252	Trial comparisons

1 to 10 of 57

See all 57 comparisons in its trials

Papers from its trials73

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35306553	RESULT	1	PubMed
33188747	RESULT	1	PubMed
29702300	RESULT	1	PubMed
28939374	RESULT	1	PubMed
28707796	RESULT	2	PubMed
28707787	RESULT	2	PubMed
28543263	RESULT	2	PubMed
27556065	RESULT	1	PubMed
24793028	RESULT	1	PubMed
24440672	RESULT	1	PubMed

1 to 10 of 73

See all 73 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL704

GET https://conductscience.org/api/drugs/v1/CHEMBL704/diseases?page=2

API reference For AI assistants